timothy sykes logo
REGN Surges As Regeneron Smashes Q3 Earnings And Wins Upgrades Thumbnail
G Google News

REGN Surges As Regeneron Smashes Q3 Earnings And Wins Upgrades

ELLIS HOBBS•UPDATED OCT. 31, 2026, 11:04 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Regeneron Pharmaceuticals Inc. stocks have been trading up by 13.1 percent following highly positive news on its latest drug developments.

What Traders Need To Know

  • Regeneron posted an exceptionally strong Q3 2026 with 36% total revenue growth and 70% non-GAAP EPS growth, driven by Dupixent, EYLEA HD, and Libtayo.
  • Q3 adjusted EPS hit $20.07 versus $16.42 consensus on revenue of $5.12B versus $4.56B, marking a major beat.
  • Shares jumped 7–13% after the report, making REGN a top Nasdaq gainer in a weak tape.
  • The Sanofi alliance was extended with $1B upfront and up to $7B in milestones, reinforcing collaboration-driven growth.
  • Multiple banks raised price targets and reiterated positive ratings on REGN following and around the Q3 print.

Candlestick Chart

Weekly Update Oct 26 – Oct 30, 2026: On Saturday, October 31, 2026 Regeneron Pharmaceuticals Inc. stock [NASDAQ: REGN] is trending up by 13.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Regeneron is a top-tier large-cap biotech with big-pharma-like fundamentals and a still-attractive growth profile. Revenue of ~$14.3B growing mid‑single digits historically understates current inflection given 36% Q3 growth. Profitability is elite (EBIT margin 30.6%, gross margin 88.6%, ROE ~18%), underpinned by a durable Dupixent/Eylea/Libtayo triad. Balance sheet strength is exceptional (net cash, D/E 0.09, interest coverage 95.5, current ratio 3.3). Valuation at ~18.5x trailing EPS and ~5x sales is reasonable versus peers given pipeline depth and accelerating cash generation (Q3 FCF $1.48B).

Technically, REGN is in a strong, momentum-driven uptrend. The weekly sequence from ~$808 to $926 reflects a clean breakout week, with the main expansion bar on 10/30 ($920–930 range) confirming institutional buying; intraday 5‑minute tape shows sustained high volume into the close rather than exhaustion. The prior congestion zone near $820 now converts to first key support and a tactical add-on level on pullbacks. Upside, the breakout bar high/close cluster around $930 is immediate resistance; a decisive, volume-backed close above $930 opens a path toward four digits.

Fundamentally and versus Healthcare and Biotech benchmarks, Regeneron screens superior on growth, margins, balance sheet quality, and pipeline breadth. Recent catalysts—blowout Q3, strengthened Sanofi alliance, Libtayo C‑POST survival data, Inmazeb BARDA extension, and new rare-disease approval—justify the wave of target hikes (now largely $980–$1,050) and >70 EPS power in 2026–2027. I expect REGN to outperform XLV and XBI over 12–18 months, with a reasonable upside target of $1,000 and key downside support at $820.

More Breaking News

Quick Financial Overview

Regeneron Pharmaceuticals Inc. delivered a textbook momentum quarter. Q3 2026 revenue reached $5.12B, well ahead of the roughly $4.56B expectation, powering 36% year-over-year growth. Non-GAAP EPS climbed 70% to $20.07, beating the $16.42 consensus by a wide margin. The key engines were surging Dupixent collaboration profits, rapid adoption of EYLEA HD, and strong Libtayo growth, backed by nearly four-year C-POST survival data in high-risk skin cancer.

Under the hood, Regeneron Pharmaceuticals Inc. is running with elite margins. Gross margin sits near 88.6%, while EBIT margin above 30% and profit margin around 28% show strong pricing power and operating discipline. Returns on equity and capital in the mid-teens, combined with very low leverage (total debt-to-equity about 0.09 and interest coverage near 95.5), give the company plenty of balance sheet flexibility. Cash generation is solid: quarterly operating cash flow of about $1.78B and free cash flow near $1.48B support ongoing buybacks, a modest dividend, and stepped-up R&D.

The tape confirmed the fundamentals. On the weekly chart, REGN exploded from the low $800s to close near $926 by the end of the week, with the biggest move landing right after earnings. Intraday, the stock swung between roughly $839 and $935 before settling near the highs, signaling strong dip buying and aggressive chasing. A trailing P/E around 18.5 and price-to-sales near 5 reflect a premium, but not a bubble, especially as multiple banks hiked price targets toward or above $1,000 on the back of the Q3 beat, EYLEA HD mix shift, and the extended Sanofi alliance with $1B upfront and up to $7B in milestones.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”